© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Celcuity Inc. (CELC) stock declined over -4.71%, trading at $85.84 on NASDAQ, down from the previous close of $90.08. The stock opened at $88.37, fluctuating between $84.80 and $89.48 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 09, 2026 | 92.00 | 93.80 | 90.00 | 90.08 | 708.27K |
| Sep 08, 2026 | 93.62 | 97.43 | 92.61 | 93.02 | 940.41K |
| Sep 04, 2026 | 95.83 | 97.25 | 94.55 | 95.70 | 515.51K |
| Sep 03, 2026 | 97.11 | 98.00 | 94.92 | 96.43 | 773.23K |
| Sep 02, 2026 | 93.61 | 96.94 | 92.13 | 96.20 | 818.18K |
| Sep 01, 2026 | 89.00 | 92.85 | 88.64 | 91.98 | 1.16M |
| Aug 31, 2026 | 87.61 | 89.81 | 86.99 | 89.06 | 785.77K |
| Aug 28, 2026 | 91.90 | 92.48 | 88.23 | 88.44 | 610.27K |
| Aug 27, 2026 | 95.06 | 95.06 | 92.54 | 93.24 | 457.27K |
| Aug 26, 2026 | 92.38 | 96.16 | 91.02 | 95.08 | 655.42K |
| Aug 25, 2026 | 92.47 | 94.33 | 91.68 | 92.27 | 681.6K |
| Aug 24, 2026 | 93.47 | 93.47 | 90.75 | 90.79 | 514.11K |
| Aug 21, 2026 | 91.39 | 95.46 | 90.51 | 93.53 | 888.29K |
| Aug 20, 2026 | 92.90 | 93.36 | 90.26 | 90.57 | 936.89K |
| Aug 19, 2026 | 95.50 | 96.01 | 91.85 | 93.65 | 591.54K |
| Aug 18, 2026 | 92.38 | 94.12 | 91.29 | 93.24 | 530.4K |
| Aug 17, 2026 | 92.99 | 93.00 | 90.59 | 92.44 | 900.93K |
| Aug 14, 2026 | 83.04 | 95.56 | 83.04 | 92.00 | 1.33M |
| Aug 13, 2026 | 92.08 | 92.99 | 86.41 | 86.60 | 1.42M |
| Aug 12, 2026 | 88.72 | 92.56 | 88.05 | 92.08 | 795.2K |
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
| Employees | 155 |
| Beta | 0.16 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |